By putting the consumer at the center of everything we do, we believe we can more effectively and equitably transition smokers to less harmful alternatives.

We believe reducing harm for adult smokers can only be successful if these consumers find potentially reduced-risk products “satisfying” – a term with a wide-ranging definition based on the diversity of adult smokers’ interests. 

Our goal is to provide adult smokers with a variety of satisfying smoke-free options and guide them responsibly towards these alternatives.

Our companies focus on developing, manufacturing and marketing products and brands that meet three important consumer expectations:

 

  • superior sensory experiences and nicotine satisfaction;
  • reduced health risks and accurate relative risk information; and
  • the ability to avoid social friction associated with cigarettes, such as smoke odor, ash and social isolation.

Moving Beyond Smoking

Altria’s companies are leading the way in moving adult smokers away from cigarettes – by taking action to transition millions toward potentially less harmful choices. Learn More

Over decades, we have built a deep understanding of adult tobacco consumers, the role tobacco products play in their lives, and why they choose specific products and brands. Recently we:

  • conducted research with approximately 50,000 consumers;
  • analyzed more than four billion consumer transactions at retail; and
  • engaged with consumers millions of times with our brands.

 

Science and research are critical to developing innovative smoke-free products and gathering scientific data for Food & Drug Administration (FDA) product applications. We're developing products backed by rigorous science and evidence to support FDA authorization.

Building Empathy for the Adult Smoker through Ethnographic Research and Insights

Reducing harm of tobacco products is a critical focus for our work. I believe our research into adult tobacco consumer behavior provides greater understanding of the transition journey from combustible cigarettes to smoke-free tobacco products.

Smoke-free Product Platforms

Our portfolio approach expands choice for adult tobacco consumers across three of the most promising smoke-free product platforms with the potential to reduce harm: oral tobacco, e-vapor and heated tobacco. These include:

Oral Tobacco – Smokeless Tobacco

U.S. Smokeless Tobacco Company is the most profitable moist smokeless tobacco (MST) company, anchored by Copenhagen®, the leading MST brand, Skoal®, Red Seal® and Husky®.

Oral Tobacco – Nicotine Pouches

on!® has a premium portfolio of product offerings across a variety of flavors and nicotine strengths.

on! PLUS® is a spit-free nicotine pouch product that uses our proprietary “soft-feel” material. It's currently in limited distribution in Sweden and the UK, and we plan to submit to the FDA a Premarket Tobacco Application. 

E-Vapor

On June 1, 2023, Altria completed its acquisition of NJOY Holdings, Inc. NJOY’s product portfolio includes NJOY ACE®* and NJOY DAILY®, the first e-vapor products to receive market authorizations from the FDA for both tobacco and menthol variants. Currently, NJOY is the only FDA authorized menthol e-vapor product. Read Press Release

Heated Tobacco Products

We have a majority-owned joint venture with JT Group, called Horizon Innovations, for the U.S. marketing and commercialization of heated tobacco stick products. We’re working toward a PMTA submission for Ploom® through our partnership with JT Group, and we’re separately continuing internal development of SWIC®, an innovative heated tobacco capsule product.

Did you Know?

92% of health care professionals;
89% of policy professionals;
79% of adult cigarette smokers 21+; and
78% of general population adult 21+
surveyed say it is important for the FDA to focus on making smoke-free tobacco products available to adults who can’t or won’t quit smoking to help them switch from cigarettes, the most harmful form of tobacco, and

98%
of health care professionals;
93%
of policy professionals;
89% of general population adults 21+; and
89% of adult cigarette smokers 21+
surveyed agree that the FDA has a responsibility to accurately inform adults who use tobacco about the different levels of harm associated with different tobacco products.1

View Survey Results


You May Also Like

Our Purpose Guides Us

As we explore future business opportunities beyond nicotine, we’ll be seeking to elevate new everyday moments for an even broader consumer base.

Innovate With Us

We believe true innovation involves collaboration and engagement. If you have a concept, methodology or other technology you would like to share, visit the Altria Open Innovation Portal.

* Due to orders issued by the International Trade Commission, effective March 31, 2025, NJOY is prohibited from importing, marketing, selling and distributing NJOY ACE devices and pods in the United States.

1 Altria Client Services Tobacco Harm Reduction (THR) Engagement Survey fielded nationwide from October 31, 2023 through November 20, 2023 among n=1,503 general population adults 21+ (MOE +/- 2.3%), n=406 adults 21+ who smoke cigarettes (MOE +/- 4.8%), n=300 other health care providers (MOE +/- 5.6%), and n=300 policy professionals (MOE +/- 5.6%). Results have been weighted by age, gender and tobacco product usage to match current U.S. population data.